Dr. Grivas on Cabazitaxel/Enzalutamide in mCRPC

Partner | Cancer Centers | <b>SCCA</b>

Petros Grivas, MD, PhD, physician, Seattle Cancer Care Alliance; associate professor, Department of Medicine, Division of Oncology and clinical director of the Genitourinary Cancers Program, University of Washington School of Medicine; and associate member, Clinical Research Division, Fred Hutchinson Cancer Center, discusses the combination of cabazitaxel and enzalutamide (Xtandi) in metastatic castration-resistant prostate cancer (mCRPC).

Petros Grivas, MD, PhD, physician, Seattle Cancer Care Alliance; associate professor, Department of Medicine, Division of Oncology and clinical director of the Genitourinary Cancers Program, University of Washington School of Medicine; and associate member, Clinical Research Division, Fred Hutchinson Cancer Center, discusses the combination of cabazitaxel and enzalutamide (Xtandi) in metastatic castration-resistant prostate cancer (mCRPC).

Once a drug has shown activity as a single agent, it is typically evaluated in combination, explains Grivas. Such was the rationale for a phase I/II study (NCT02522715) with the chemotherapy agent cabazitaxel and the novel antiandrogen enzalutamide, which are both approved for use as monotherapy in mCRPC.

In the phase I portion of the trial, no dose-limiting toxicities were observed with the combination. The phase II results, which were presented at the 2020 Genitourinary Cancers Symposium, showed encouraging prostate-specific antigen (PSA) response rates with the combination with a manageable safety profile, says Grivas. Among 36 evaluable patients, 56% had a ≥90% decrease in PSA. These results merit further investigation in a phase III trial, concludes Grivas.